New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease
Halting the reduction in glomerular filtration rate (GFR) is the primary aim of any treatment of patients presenting with progressive chronic renal failure, a very common corollary to diabetes. To improve GFR, the high blood pressure (BP) and proteinuria often seen in these patients must both be con...
Main Author: | Luis M Ruilope |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publications
2000-06-01
|
Series: | Journal of the Renin-Angiotensin-Aldosterone System |
Online Access: | http://jra.sagepub.com/content/1/2_suppl/S29.full.pdf |
Similar Items
-
New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease
by: Luis M Ruilope
Published: (2000-06-01) -
Combination of aliskiren with angiotensin-converting enzyme-inhibitor and angiotensin receptor blocker — mechanism of action
by: Luis M Ruilope
Published: (2008-03-01) -
Angiotensin II type 1 receptor blockers favorably affect renal angiotensin II and MAS receptor expression in patients with diabetic nephropathy
by: Ye-Ping Ma, et al.
Published: (2020-05-01) -
Clinical pharmacogenetics of angiotensin II receptor blockers in Iraq
by: Hany A Al-Hussaniy, et al.
Published: (2023-01-01) -
Clinical pharmacology of angiotensin II receptor blockers: valsartan
by: M. V. Leonova
Published: (2014-12-01)